Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma

European Urology

Volumn 63, Issue 5, 2013, Pages 947-952

  Margulis, Vitaly ^a   Shariat, Shahrokh F ^b   Rapoport, Yury ^a   Rink, Michael ^b   Sjoberg, Daniel D ^c   Tannir, Nizar M ^d   Abel, E Jason ^d   Culp, Stephen H ^d   Tamboli, Pheroze ^d   Wood, Christopher G ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytoreductive nephrectomy; Oncologic outcome; Prediction models; Renal cell carcinoma

Indexed keywords

LACTATE DEHYDROGENASE; SERUM ALBUMIN;

ACCURACY; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; CANCER CENTER; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIMULATION; TRANSFUSION;

BLOOD TRANSFUSION; CARCINOMA, RENAL CELL; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY NEOPLASMS; L-LACTATE DEHYDROGENASE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEPHRECTOMY; ODDS RATIO; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SERUM ALBUMIN; TERTIARY CARE CENTERS; TEXAS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84876038850     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.11.040     Document Type: Article

References (28)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. J.M. Hollingsworth, D.C. Miller, S. Daignault, and B.K. Hollenbeck Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis Cancer 109 2007 1763 1768
3. W.H. Chow, and S.S. Devesa Contemporary epidemiology of renal cell cancer Cancer J 14 2008 288 301
4. G.H. Mickisch, A. Garin, H. van Poppel, L. de Prijck, and R. Sylvester Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
5. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
6. R.C. Flanigan, G. Mickisch, R. Sylvester, C. Tangen, H. Van Poppel, and E.D. Crawford Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 2004 1071 1076
7. R.J. Halbert, R.A. Figlin, and M.B. Atkins Treatment of patients with metastatic renal cell cancer: a RAND appropriateness panel Cancer 107 2006 2375 2383
8. V. Margulis, and C.G. Wood Pre-surgical targeted molecular therapy in renal cell carcinoma BJU Int 103 2009 150 153
9. V. Margulis, C.G. Wood, E. Jonasch, and S.F. Matin Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors Curr Oncol Rep 10 2008 253 258
10. P.L. Ross, C. Gerigk, and M. Gonen Comparisons of nomograms and urologists' predictions in prostate cancer Semin Urol Oncol 20 2002 82 88
11. M.C. Specht, M.W. Kattan, M. Gonen, J. Fey, and K.J. Van Zee Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram Ann Surg Oncol 12 2005 654 659
12. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
13. A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565 574
14. A.J. Vickers Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers Am Stat 62 2008 314 320
15. P.L. Crispen, and M.L. Blute Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma Curr Urol Rep 13 2012 38 46
16. R.J. Motzer, R.M. Bukowski, and R.A. Figlin Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552 1558
17. T.K. Choueiri, B. Rini, and J.A. Garcia Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma Ann Oncol 18 2007 249 255
18. K.R. Han, A.J. Pantuck, and M.H. Bui Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma Urology 61 2003 314 319
19. S. Negrier, F. Gomez, and J.Y. Douillard Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie World J Urol 23 2005 161 165
20. T.K. Choueiri, J.A. Garcia, and P. Elson Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy Cancer 110 2007 543 550
21. P.M. Pierorazio, J.M. McKiernan, T.R. McCann, S. Mohile, D. Petrylak, and M.C. Benson Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed BJU Int 100 2007 755 759
22. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
23. S. Ramsey, G.W. Lamb, M. Aitchison, J. Graham, and D.C. McMillan Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer Cancer 109 2007 205 212
24. J.R. Vasselli, J.C. Yang, W.M. Linehan, D.E. White, S.A. Rosenberg, and M.M. Walther Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma J Urol 166 2001 68 72
25. S.H. Culp, N.M. Tannir, and E.J. Abel Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116 2010 3378 3388
26. R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463
27. P.I. Karakiewicz, M. Sun, J. Bellmunt, V. Sneller, and B. Escudier Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria Eur Urol 60 2011 48 56
28. T.K. Choueiri, W. Xie, and C. Kollmannsberger The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy J Urol 185 2011 60 66